Cyclopharm Ltd
ASX:CYC
Net Margin
Cyclopharm Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
C
|
Cyclopharm Ltd
ASX:CYC
|
97.8m AUD |
-48%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.3B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.1B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.7B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144.1B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.6B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.4B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.2B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.2B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.8B CNY |
31%
|
Cyclopharm Ltd
Glance View
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cyclopharm Ltd's most recent financial statements, the company has Net Margin of -47.9%.
You don't have any saved screeners yet